VistaGen Therapeutics Q2 EPS $(0.24) Beats $(0.38) Estimate, Sales $138.000K Miss $250.000K Estimate

Benzinga · 1d ago
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.38) by 35.14 percent. This is a 55.56 percent increase over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $138.000 thousand which missed the analyst consensus estimate of $250.000 thousand by 44.80 percent. This is a 46.51 percent decrease over sales of $258.000 thousand the same period last year.